Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma

The Oncologist
Harry YoonMichael K Gibson

Abstract

Panitumumab plus irinotecan is not active for the treatment of esophageal adenocarcinoma. Esophageal adenocarcinoma (EAC) is a lethal cancer with increasing incidence. Panitumumab (Pa) is a fully humanized IgG2 monoclonal antibody against human EGFR. Cetuximab (Cx) combined with irinotecan (Ir) is active for second-line treatment of colorectal cancer. This phase II study was designed to evaluate Pa plus Ir as second-line therapy for advanced EAC. The primary endpoint was response rate (RR). Patients with one prior treatment were given Pa 9 mg/m2 on day 1 and Ir 125 mg/m2 on days 1 and 8 of each 21-day cycle. Inclusion criteria were confirmed EAC, measurable disease, no prior Ir or Pa, performance status <2, and normal organ function. Twenty-four patients were enrolled; 18 were eligible and evaluable. These patients were all white, with a median age of 62.5 years (range, 33-79 years), and included 15 men and 3 women. The median number of cycles was 3.5. The most common grade 1-2 adverse events were fatigue, diarrhea, anemia, leukopenia, and hypoalbuminemia. Grade 3-4 adverse events included hematologic, gastrointestinal, electrolyte, rash, fatigue, and weight loss. The median follow-up was 7.2 months (range, 2.3-14 months). Ther...Continue Reading

Associated Clinical Trials

Feb 4, 2009·Weijing Sun, MD, FACP, Weijing Sun, MD, FACP

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John Mendelsohn, Jose Baselga
Feb 18, 2004·International Journal of Radiation Oncology, Biology, Physics·Kenneth A FoonGisela M Schwab
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemRafael G Amado
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaffer A AjaniUNKNOWN V-325 Study Group
Jan 4, 2008·The New England Journal of Medicine·David CunninghamUNKNOWN Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel TepperRobert Mayer
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
May 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemManish A Shah
Jun 1, 2012·The New England Journal of Medicine·P van HagenUNKNOWN CROSS Group
Feb 5, 2013·Lancet·Arjun PennathurJames D Luketich
Apr 19, 2013·The Lancet Oncology·Florian LordickUNKNOWN Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators
Jul 6, 2014·The Lancet Oncology·Yu SunakawaYasutsuna Sasaki
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Nov 9, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toshihiko DoiJaafar Bennouna

❮ Previous
Next ❯

Citations

Apr 2, 2019·Current Topics in Medicinal Chemistry·Wenjie Wang, Yuk-Ching Tse-Dinh
Dec 29, 2020·Frontiers in Oncology·Steven B MaronYelena Y Janjigian
Jun 4, 2019·Biochimica Et Biophysica Acta. Reviews on Cancer·Ravindran Caspa GokulanAlexander I Zaika

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.